**Published Ahead of Print on August 21, 2023 as 10.1212/WNL.0000000000207726**

Neurology®

The most widely read and highly cited peer-reviewed neurology journal
The Official Journal of the American Academy of Neurology

AMERICAN ACADEMY OF NEUROLOGY®

**Neurology Publish Ahead of Print**
**DOI: 10.1212/WNL.0000000000207726**

# Relation of Motor Impairments to Neuropathologic Changes of Limbic-Predominant Age-Related TDP-43 Encephalopathy in Older Adults

**Author(s):**
Shahram Oveisgharan, MD[1,2]; Lei Yu, PhD[1,2]; Sonal Agrawal, PhD[1,3]; Sukriti Nag, MD, PhD[1,3]; David A. Bennett, MD[1,2]; Aron S. Buchman, MD[1,2]; Julie A. Schneider, MD[1,2,3]

**Corresponding Author:**
Shahram Oveisgharan, shogh2@yahoo.com

**Affiliation Information for All Authors:** 1. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; 2. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA; 3. Department of Pathology, Rush University Medical Center, Chicago, IL, USA.

**Equal Author Contribution:**

**Contributions:**
Shahram Oveisgharan: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data
Lei Yu: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data
Sonal Agrawal: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Sukriti Nag: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
David A. Bennett: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Aron S. Buchman: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data
Julie A. Schneider: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

**Figure Count:**
2

**Table Count:**
3

**Search Terms:**
[ 25 ] All Cognitive Disorders/Dementia, [ 26 ] Alzheimer's disease, [ 29 ] Frontotemporal dementia, [ 178 ] Amyotrophic lateral sclerosis

**Acknowledgment:**
We thank the study participants and the staff of the Rush Alzheimer's Disease Center.

**Study Funding:**
The study was supported by NIH grants R01AG067482, P30AG10161, P30AG72975, R01AG15819, R01AG17917, R01AG075728, R01AG056352.

**Disclosure:**
All authors report no disclosures relevant to the manuscript.

**Preprint DOI:**

**Received Date:**
2023-02-08

**Accepted Date:**
2023-06-14

**Handling Editor Statement:**
Submitted and externally peer reviewed. The handling editor was Associate Editor Linda Hershey, MD, PhD, FAAN.

## ABSTRACT

**Background:** Limbic-predominant age-related transactive response DNA-binding protein 43 (TDP-43) encephalopathy-neuropathologic change (LATE-NC) is common and is a major contributor to cognitive decline and Alzheimer's dementia in older adults. The objective of the current study was to examine whether LATE-NC was also associated with declining motor function in older adults.

**Methods:** Participants were from 2 longitudinal clinical pathological studies of aging who did not have dementia at the time of enrollment. Postmortem pathological exam included immunohistochemical staining for TDP-43 in 8 brain regions, which was summarized as a dichotomous variable indicating advanced LATE-NC stages at which TDP-43 pathology had accumulated in the hippocampus, entorhinal or neocortical regions. Annual motor testing included maximal inspiratory and expiratory pressures (summarized as respiratory muscle strength), grip and pinch strength (summarized as hand strength), finger tapping speed and the Purdue Pegboard test (summarized as hand dexterity), walking 8 feet and turning $360^{o}$ (summarized as gait function). The severity of parkinsonism was also assessed and summarized as global parkinsonism score. Global cognition was a summary of standardized scores of 19 neuropsychological tests. We used linear mixed effects models to examine the associations of LATE-NC with longitudinal changes of motor decline, and used multivariate random coefficients models to simultaneously examine the associations of LATE-NC with cognitive and motor decline.

**Results:** Among 1483 participants (mean age at death 90.1 (SD=6.4) years, 70% women, mean follow up 7.4 (SD=3.8) years), LATE-NC was present in 34.0% (n=504). In separate linear mixed effects models controlling for demographics and other brain pathologies, LATE-NC was

associated with faster decline in respiratory muscle strength (Estimate=-0.021, SE=0.007, p=0.005) and hand strength (Estimate=-0.005, SE=0.002, p=0.005), but was not related to hand dexterity, gait function, or parkinsonism. In multivariate random coefficients models including respiratory muscle strength, hand strength, and global cognition as the outcomes, LATE-NC remained associated with faster respiratory muscle strength decline rate (Estimate=-0.021, SE=0.009, p=0.023), but the association with hand strength was no longer significant (Estimate=-0.002, SE=0.003, p=0.390).

**Discussion:** Motor impairment, specifically respiratory muscle weakness, may be an unrecognized co-morbidity of LATE-NC, that highlights the potential association of TDP-43 proteinopathy with non-cognitive phenotypes in aging adults.

**Key words:** LATE-NC; TDP-43; Motor function; Respiratory muscle strength; Hand strength.

## INTRODUCTION

Limbic-predominant age related TDP-43 encephalopathy (LATE) was first coined in 2019 by a working group to describe an age-related neurocognitive syndrome characterized by progressive cognitive decline yielding disability in activities of daily living and dementia[1]. Neuropathologic changes of LATE (LATE-NC) are present in more than one third of adults older than 80 years[2], and may contribute to 17% of dementia cases of Alzheimer's types[1].

Inclusions of transactive response DNA binding protein 43 kDa (TDP-43), including round neuronal cytoplasmic inclusions and ropy neurites, are hallmarks of LATE-NC[3]. Besides LATE-NC, TDP-43 inclusions are also seen in other brain diseases, most persons with amyotrophic lateral sclerosis (ALS)[4] and in a subset of patients with frontotemporal lobar degeneration (FTLD)[5]. The predominant deficit in a motor neuron disease such as ALS is muscle weakness, with respiratory muscle deficits a crucial determinant of survival[6]. Nonetheless, impaired cognition has been reported in up to 50% of ALS patients[7], and 10-15% of ALS patients develop dementia[7]. Similarly, 10% of frontotemporal dementia patients also have signs and symptoms of motor neuron disease[8]. While prior studies have examined both motor and cognitive dysfunctions in more familiar TDP-43 related neurological syndromes, few studies have examined motor impairment in older adults with LATE-NC[9].

The primary objective of the current study was to examine whether LATE-NC was associated with declining motor function in older adults. The secondary objective was examining whether LATE-NC was differentially associated with motor decline and cognitive decline considering the strong correlation between the rate of change of cognitive and motor decline in older adults.

## METHODS

### Participants

To achieve the study objectives, we used data from participants of two ongoing clinical-autopsy cohort studies of aging, the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP)[10]. ROS and MAP both recruit older adults without known dementia at the time of enrollment that consent to annual clinical evaluations as well as brain autopsy at the time of death. ROS began enrollment in 1994 recruiting nuns, priests, and brothers across the United States. MAP began enrollment in 1997 recruiting Illinoisans living in retirement centers and single-family dwellings across northeastern Illinois. Harmonized study protocols with identical clinical and postmortem data collection methods performed by the same staff facilitated joint analyses. Additional details about the design and instruments employed in both studies are provided in prior publications[10].

Since the main objective of the current study was to examine whether declining motor function in older adults was associated with LATE-NC, we excluded participants with a pathological diagnosis of FTLD. At the time of the study analyses, 2112 of 3690 recruited participants had died, and 1725 had undergone autopsy with completed postmortem examinations, of whom 1483 composed the analytic sample of the current study as they did not have a pathological diagnosis of FTLD and had 2 or more assessments of motor functions. Of note, 7.1% (n=54) and 13.3% (n=122) of participants with and without dementia prior to death, respectively, were excluded because of not having 2+ motor assessments including hand strength, which indicated that our analytic sample size was not biased by inadequate inclusion of participants with dementia.

**Postmortem assessment of brain pathologies**

The median (IQR) of postmortem intervals was 6.8 (5.1–10.3) hours. After brain removal, one hemisphere was frozen for multi-omics studies, and the other hemisphere was fixed in 4% formaldehyde in phosphate buffer. The fixed hemisphere was cut into 1-cm thick slabs and tissue blocks and sections were prepared from predetermined regions for the pathological assessments. Additional details of the autopsy procedures are provided elsewhere[11].

*LATE-NC.* Sections of 8 brain regions were immunohistochemically examined using a phosphorylated monoclonal TAR5P-1D3 anti-TDP-43 antibody (pS409/410; 1:100). The examined brain regions were the amygdala, hippocampus (CA1, subiculum), dentate gyrus, entorhinal cortex, and neocortices (orbital frontal, midfrontal, anterior temporal, and middle temporal cortices). Abnormally phosphorylated TDP-43 inclusions in the cytoplasm of the neurons and glia were detected and manually counted in a 0.25 $mm^2$ area with the greatest density[12]. We used a modified LATE-NC working group recommendation[13,14] to summarize burden of TDP-43 inclusions in 4 stages. Stage 0 indicated no TDP-43 inclusions; stage 1 indicating TDP-43 inclusions in amygdala only; stage 2 extension to the hippocampus, dentate gyrus, or entorhinal cortex; stage 3 extension into the neocortices. In this study, we used a dichotomous variable indicating TDP-43 was in the entorhinal, hippocampus, or beyond (stages 2-3).

*Alzheimer's disease (AD).* A modified silver Bielschowsky stain was used for visualizing diffuse plaques, neuritic plaques, and neurofibrillary tangles in sections of 5 brain regions[15]. A Board-certified neuropathologist blinded to clinical data adjudicated pathological AD diagnosis[16].

*Hippocampal sclerosis.* Coronal sections of the mid hippocampus were examined for the presence of hippocampal sclerosis, which was summarized using a dichotomous variable indicating severe neuronal loss and gliosis in CA1 and/or subiculum[17].

*Parkinson's disease (PD).* Antibodies against α-synuclein were used for detection of Lewy bodies, which were summarized using a dichotomous variable indicating presence of Lewy bodies. At the level of 3rd nerve exit root, sections of midbrain containing substantia nigra were stained with H&E. Nigral neuronal loss was assessed using a semiquantitative scale (none, mild, moderate, severe). PD pathology was defined by a dichotomous variable indicating presence of Lewy bodies and moderate to severe nigral neuronal loss[18].

*Macroinfarcts.* Slabs of the fixed hemisphere and photographs of slabs of the frozen hemisphere were examined for presence of macroinfarcts, which were confirmed microscopically[19]. We included only chronic macroinfarcts, summarized by a dichotomous variable, because the pathologies affect progressive motor decline that occur over years of follow up.

*Microinfarcts.* A minimum of 9 brain regions were examined microscopically for detection of microinfarcts using H&E stained sections. Like macroinfarcts, only chronic microinfarcts were included that were summarized using a dichotomous variable[19].

*Atherosclerosis.* Circle of Willis vessels and their proximal branches were examined for atherosclerosis[20], which was summarized using a dichotomous variable indicating presence of moderate to severe atherosclerosis.

*Arteriolosclerosis.* H&E sections of the anterior basal ganglia region were examined for arteriolosclerosis[19], which was summarized using a dichotomous variable indicating presence of moderate to severe arteriolosclerosis.

*Cerebral amyloid angiopathy (CAA).* Immunohistochemical methods was used for detection of mural amyloid-β in the meningeal and parenchymal vessels of 4 brain regions, which was summarized using a dichotomous variable indicating presence of moderate to severe CAA[19].

**Assessment of motor function**

Multiple motor performances were tested to capture the heterogeneity of late-life motor impairment in aging adults and considering the well-recognized distribution of weakness in ALS, another TDP-43 related syndrome. In prior publications we developed composite measures of the diverse motor performances. Using composite measures was done to minimize random errors and floor and ceiling effects associated with examination of individual motor performances, and provided more power in examining associations between LATE-NC and declining motor function[18,21].

*Hand strength*. Grip and pinch strength were measured annually using a hand-held dynamometer (Lafayette Instruments, Lafayette, Ind., USA). Participants were asked to perform each test with each hand twice. The average of the 4 trials for each test was calculated representing grip strength and pinch strength in pounds of pressure. Stratified by sex, the grip and pinch strength were separately standardized using the baseline mean and standard deviation of the tests in each sex. Then, the standardized grip and pinch strength scores were averaged to make hand strength composite variable.

*Respiratory muscle strength.* A hand-held device that contained a pressure transducer sensor (MicroMouth Pressure Meter MP01; MicroMedical Ltd., Kent, UK) was used for respiratory muscle strength measurements, which was performed only in MAP. Participants were asked to take a deep breath, seal their lips around the mouthpiece of the device, maximally expire and

hold their maximal expiration for at least 1 second. This performance was done twice for measurement of maximal expiratory pressure (MEP) in cm $H_2O$. Similar testing was employed to measure maximal inspiratory pressure (MIP). The 2 MEP and MIP performances were averaged separately. Initial review of our data showed that men had higher MEP and MIP scores. So, women's and men's MEP and MIP scores were divided by their corresponding sex-specific averages of baseline MEP and MIP, and respiratory muscle strength was the average of these fractions multiplied by 100. Therefore, an average woman or man had a score of 100 at baseline with higher scores indicating higher respiratory muscle strength.

*Other motor functions.* Other motor function composite variables were hand dexterity (derived from finger tapping speed and Purdue Pegboard test), gait (derived from steps and time to complete walking 8 feet and turning 360$^o$ twice), and parkinsonism severity score (assessed using Unified Parkinson's Disease Rating Scale). Details of these motor function assessments are provided in the eMethods and elsewhere[18,22–24].

**Assessment of cognition and diagnosis of dementia**

At annual assessments, a battery of 19 neuropsychological tests were administered whose scores were standardized using means and standard deviations of the tests at baseline. The standardized scores were averaged to make a global cognition score[25]. Moreover, the tests' scores were reviewed and rated by a neuropsychologist blinded to clinical data. The neuropsychologist's ratings together with clinical and physical examination data were reviewed by a neurologist and cognition status of the participants including presence of dementia was determined[26].

**Covariates.**

Sex was determined by self-report. Age at death was calculated using reported dates of birth and death.

**Statistical analyses**

Categorical and continuous data were compared between higher and lower stages of LATE-NC by $\chi^2$ and t-test, respectively. We used linear mixed effects models to examine associations of LATE-NC with longitudinal changes of motor decline. The core model consisted of fixed effects for age at death, sex, time (slope of motor decline), and interactions of age and sex with time, and random intercept and slope. The random effects account for person-specific level of motor function and person-specific rate of motor decline. Then, we added terms for LATE-NC and its interaction with time to examine if LATE-NC was associated with level of motor function and rate of motor decline, respectively. As most participants had multiple brain pathologies that might affect motor function, in subsequent models we controlled the associations of LATE-NC with motor decline for other brain pathologies.

Prior work has generally examined longitudinal change of different phenotypes like motor and cognitive function in separate models. However, an individual experiences change of both motor and cognitive function. Therefore, to account for the correlations between changes of cognitive and motor functions in older adults we used multivariate random coefficients models that simultaneously estimated levels of cognition and motor function and their rates of decline. For these analyses, we standardized respiratory muscle strength using its baseline mean and standard deviation to make the 3 outcomes of the same measurement unit. Then, we added terms for LATE-NC to examine whether LATE-NC was differentially associated with global cognition

and motor function. The analysis was controlled for age at death and sex and their interaction with time. Two-sided P-values less than 0.05 were used for rejecting null hypotheses.

**Standard Protocol Approvals, Registrations, and Patient Consents**

Each study was approved by the Institutional Review Board at Rush University Medical Center. The IRB approval numbers are L91020181 (ROS) and L86121802 (MAP). All participants signed an Anatomic Gift Act and informed consent.

**Data availability**

The application process to obtain the data is initiated by filling an application including a short study premise and a brief research plan. The application should be submitted at the Rush Alzheimer's Disease Center Research Resource Sharing Hub at *www.radc.rush.edu*. Almost all applications get approved.

**RESULTS**

**Clinical and pathological characteristics of participants**

The characteristics of the 1483 older adults, who were followed for an average 7.4 years (SD = 3.8) before death, are summarized in Table 1. The average age at death was 90 years. Participants with LATE-NC were on average 3 years older than participants without LATE-NC. AD, hippocampal sclerosis, and CAA pathologies were more frequent in adults with LATE-NC, but the two groups were not different in the frequency of other brain pathologies (Table 1).

**Upper extremity motor function**

*Hand strength*. Examining longitudinal assessments of hand strength over years of follow up indicated that hand strength on average declined (estimate=-0.041, SE=0.001, p<0.001). LATE-

NC was associated with a faster rate of hand strength decline and a lower level of hand strength at death (Table 2, Model 1; Figure 1). To contextualize the effect size, we used the model-derived estimates (eTable 1, Model 1). In an average 90-year old woman LATE-NC was associated with an 18.4% faster hand strength decline rate. Moreover, estimating variance of person-specific rates of hand strength decline indicated that LATE-NC explained 2.7% of the variance in the rate of hand strength decline.

We examined whether the association of LATE-NC with hand strength decline was independent of other brain pathologies. In a linear mixed effects model including terms for the examined pathologies and their interaction with time, LATE-NC remained associated with both faster hand strength decline and a lower level of hand strength at death (Table 2, Model 2; Figure 1). As LATE-NC co-occurs with AD pathology in many older adults[27] and motor impairment in older adults is also a manifestation of AD[28], we examined if presence of AD modified the association of LATE-NC with hand strength decline. In a linear mixed effects model including terms for LATE-NC, AD, their interactions with each other and with time, neither the LATE-NC×AD (estimate=-0.019, SE=0.035, p=0.591) nor LATE-NC×AD×Time (estimate=0.0003, SE=0.004, p=0.932) was significant indicating that co-morbid AD pathology in an individual with LATE-NC was not synergistically associated with hand weakness.

*Hand dexterity.* Hand dexterity on average declined during follow ups (estimate=-0.025, SE=0.001, p<0.001). LATE-NC was associated with a faster rate of hand dexterity decline and a lower level of hand dexterity at death (Table 2, Model 1). However, when we controlled for other pathologies, LATE-NC was not associated anymore with either rate of decline or level of hand dexterity at death (Table 2, Model 2).

**Gait**

Gait function also on average declined during follow ups (estimate=-0.042, SE=0.001, p<0.001). LATE-NC was associated with a faster rate of gait function decline (**Table 2, Model 1**). However, the association of LATE-NC with gait function decline rate, which persisted after controlling for other pathologies (Table 2, Model 2), was not as strong as the association with hand strength. Moreover, estimating variance of person-specific rates of gait decline indicated that LATE-NC did not explain any percentage of the variance in the rate of gait decline. These findings suggested that LATE-NC was not significantly related to gait impairment in older adults.

**Parkinsonism**

Examining longitudinal assessments of parkinsonism indicated progression of parkinsonism severity during the study (estimate=0.120, SE=0.004, p<0.001). LATE-NC was associated with a faster parkinsonism progression (Table 2, Model 1). However, the association of LATE-NC with faster rate of parkinsonism progression was attenuated and not significant anymore after controlling for other pathologies (Table 2, Model 2).

**Respiratory muscles strength**

A total of 764 participants had respiratory muscle strength assessments. Respiratory muscle strength on average declined during the study (estimate=-2.703, SE=0.175, p<0.001). LATE-NC was associated with both faster rate of respiratory muscle strength decline and a lower level of respiratory muscle strength at death (Table 2, Model 1; Figure 2). In a 90-year old woman LATE-NC was associated with 37.8% faster rate of respiratory muscle strength decline,

an effect size larger than the association of LATE-NC with hand strength decline (eTable 1, Model 2).

The association of LATE-NC with faster respiratory muscle strength decline did not change when the model was further controlled for other pathologies (**Table 2, Model 2; Figure 2**). Co-morbid AD pathology in an individual with LATE-NC was not synergistically associated with a faster respiratory muscle strength decline rate (LATE-NC×AD×Time: Estimate=0.316, SE=0.646, p=0.624) or with a lower level of respiratory muscle strength at death (LATE-NC×AD: Estimate=-1.939, SE=5.455, p=0.722).

**Sensitivity analyses**

LATE-NC is more common in older adults (Table 1)[1]. We examined whether the association between LATE-NC and faster hand strength and respiratory muscle strength decline was modified by age at death. In mixed effects models that examined the associations of LATE-NC with hand strength and respiratory muscle strength, we added a two-way interaction between LATE-NC and age and a three-way interaction between LATE-NC, age, and time. The analyses indicated that none of the interactions were significant (eTable 2), which suggested that age did not modify the association of LATE-NC with faster motor decline in older adults.

We treated LATE-NC as a dichotomous variable by combining stages 0-1 into one group and 2-3 into another group because of parsimony and because of prior studies' findings that had examined the associations of LATE-NC stages with dementia[27]. In a sensitivity analysis we examined whether use of the LATE-NC dichotomous variable in the association with motor decline was supported by the data. In 2 separate mixed effects models, we examined the association of LATE-NC with hand strength and respiratory muscle strength decline using 3

dummy variables, representing LATE-NC stages 1-3, and their interactions with time. The analyses indicated that stage 1 was not different from stage 0, and stage 3 not different from stage 2, in the associations with hand strength and respiratory muscle strength decline, which supported use of the dichotomous LATE-NC variable (eTable 3).

**Motor and cognitive function**

Cognitive and motor decline in older adults are related,[29] and cognitive decline is a known manifestation of LATE-NC[1,27]. Therefore, after showing that LATE-NC was associated with declining respiratory muscle strength and hand strength in separate models (Table 2), we tested a hypothesis that LATE-NC was differentially associated with motor decline and cognitive decline. To test this hypothesis, we first set up a model to simultaneously estimate the change in respiratory muscle strength, hand strength, and global cognition while accounting for the correlations between the 3 outcomes. Next, we examined association of LATE-NC and other pathologies with the 3 outcomes in a single model.

All participants with repeated measures of respiratory muscle strengths had also repeated measures of global cognition and hand strength. We used multivariate random coefficients models including repeated measures of respiratory muscle strength, hand strength, and global cognition to estimate the correlation structure between these 3 outcomes. In a model including age at death, sex, and their associations with the rates of decline and levels of respiratory muscle strength, hand strength, and global cognition, the estimated person specific rates of decline in the 3 outcomes were correlated (eFigure 1, eTable 4). The highest correlation was between the rate of decline in the motor outcomes (r=0.83), followed by the correlation between respiratory muscle strength and global cognition (r=0.68) and hand strength and global cognition (r=0.53) decline rates.

Next, we simultaneously examined association of LATE-NC (Table 3-Model 1), other brain pathologies (Table 3-Model 2), and all pathologies (Table 3-Model 3) with longitudinal changes of respiratory muscle strength, hand strength, and global cognition. In the first model that included only LATE-NC, LATE-NC remained associated with faster rates of decline and lower levels of respiratory muscle strength and global cognition, but the association of LATE-NC with hand strength was no longer significant (Table 3-Model 1, eTable 5-Model 1). The associations of LATE-NC with faster decline in the respiratory muscle strength and global cognition persisted after controlling for other pathologies (Table 3-Model 3, eTable 5-Model 3). Then, we compared the estimates of the associations of LATE-NC with respiratory muscle strength and global cognition decline rates, derived from the model that controlled for the other brain pathologies (Table 3-Model 3). The estimates were different (Estimate=0.023, SE=0.008, p=0.004), indicating that LATE-NC was differentially associated with cognitive and motor decline.

We also estimated how much of the variance in the respiratory muscle strength and global cognition decline rates were explained by LATE-NC. LATE-NC explained 3.9% of the variance in the respiratory muscle strength decline rate and 4.7% of the variance in the global cognition decline rate (eFigure 2).



## DISCUSSION

In a cohort of approximately 1500 participants we found that LATE-NC was associated not only with cognitive decline but with faster motor decline, specifically respiratory muscle strength. Moreover, the association of LATE-NC with faster motor decline was different from its association with faster cognitive decline. These findings suggest that LATE-NC, like other neurodegenerative pathologies including AD and PD, may have negative effects on not only

cognitive but also non-cognitive phenotypes. Moreover, considering that LATE-NC was observed in a 1/3 of our participants, the current study suggests that TDP-43 accumulating in aging brains may have a heretofore unrecognized role in the heterogeneity of late-life motor decline. Future studies are needed to explore the mechanisms underlying LATE-NC so that targeted treatments can be developed.

Since the first reports of the associations of TDP-43 inclusions with cognitive impairment in older adults in 2007[30] and development of LATE as a neurodegenerative disease of cognitive impairment in older adults[1], most studies have focused on the association of LATE-NC with cognitive impairment[2,31]. Other investigated phenotypes included behavioral manifestations of LATE-NC such as psychosis[32]. In our prior reports, we had included TDP-43 among other common age-related brain pathologies in association with 1 or 2 phenotypes of motor decline in older adults, such as parkinsonism[33] and impaired global motor function[22]. This study extends prior studies by focusing on LATE-NC and examining several phenotypes of motor impairment in older adults. Moreover, by using multivariate random coefficients models we untangled cognitive from motor decline and found that the association of LATE-NC with motor decline was different from its association with cognitive decline. Therefore, the current study findings advance the field by introducing new clinical correlates of LATE-NC that are also important from the public health view as incident motor impairment is very common[29] and associated with morbidity and mortality[34,35]. Moreover, the current findings suggest addition of LATE to AD and PD that are multisystem disorders affecting both cognitive and motor systems.

LATE-NC was associated with a faster respiratory muscle strength decline that was different from the association of LATE-NC with cognitive decline. Although motor and sensory cortices together with insula are also involved in respiratory control[36], the respiratory network is

mainly located in the medullary pontine junction including preBötzinger Complex[37,38], which lies close to the inferior olive[39]. Furthermore, studies that examined distribution of TDP-43 inclusions across cerebral hemispheres and brainstem found that TDP-43 inclusions were also observed in inferior olive[40]. Therefore, it is possible that LATE-NC also affects respiratory network in the medullary pontine junction, which underlies respiratory muscle strength decline. Moreover, as neurons in the medullary pontine junction are less involved in cognition this hypothesis can explain differential associations of LATE-NC with faster respiratory muscle strength decline vs. global cognition decline that is possibly caused by LATE-NC involvement of cortical regions in the brain hemispheres. Further studies are needed to examine this hypothesis.

Faster respiratory muscle strength and hand strength decline were the 2 motor impairments associated with LATE-NC. However, the effect size of the association of LATE-NC with the rate of hand strength decline was half of the effect size of the association with the rate of respiratory muscle strength decline. In addition, the association of LATE-NC with hand strength decline was attenuated in the models that also included global cognition and respiratory muscle strength as the outcomes. These findings suggest that while having weak hands is a comorbidity of LATE, LATE-NC has a preferential association with weak respiratory muscles as the motor correlate. We previously showed that weak hand strength was a risk factor for incident cognitive impairment and AD dementia[41] to which LATE-NC contributes[31]. Neuronal networks in brain regions including frontal, temporal, and insular cortices contribute to both hand strength[42] and cognitive function and are vulnerable for development of LATE-NC[1], which can explain the association of LATE-NC with both hand strength and cognitive decline.

Weakness of respiratory muscle strength[43] and hand strength[44] are also manifestations of ALS, another phenotype of TDP-43 proteinopathy. Moreover, ALS patients may have cognitive

impairment in addition to their prominent motor impairment[45]. Similarly, patients with FTLD may present with cognitive and motor impairments even during prodromal phases[5]. Therefore, TDP-43 proteinopathy may be considered as a spectrum of diseases with motor and cognitive impairments, with prominent motor impairment in one disease (ALS) and cognitive impairment in others (LATE, FTD). In fact, studies have reported that limbic-predominant TDP-43 depositions are more frequent with advancing age in patients with ALS[46] or FTLD[47], which supports TDP-43 spectrum disorders as LATE-NC is also more frequent in the oldest old. Further studies are required to uncover structures of the pathological TDP-43 aggregates across these diseases[48]. If further evidences support this spectrum, risk factors and treatments of one of the diseases in the spectrum may be beneficial in the other disease. Interestingly, diabetes mellitus has been reported as a protective factor for ALS, and we previously reported an inverse association between higher hemoglobin A1c and more severe LATE-NC[12].

We did not find consistent associations between LATE-NC and hand dexterity, gait, or parkinsonism. These null findings together with the associations of hand and respiratory muscle strengths with LATE-NC may be illustrative of the heterogeneity of motor decline in older adults. An individual may lose the ability to walk but have strong grip strength compared to another adult that walks independently but manifests hand weakness. In the current study, LATE-NC was most commonly assessed in cognitive-related brain regions. Neural systems underlying appendicular or axial motor performances extend beyond the brain to the spinal cord and muscles that may also be vulnerable to the accumulation of TDP-43 inclusions as reported in ALS[49]. The current results highlight the need for further studies with larger sample sizes that examine motor-related sites for TDP-43 inclusions within and outside the brain to determine the full extent to which TDP-43 may contribute to late-life motor impairment.

The current study has several limitations. Participants were volunteers, mostly Whites, with high educational levels. Thus, these data require replication in other more diverse populations. Although the number of brain regions assessed for the presence of TDP-43 inclusions was more than the current recommendations[1], motor-related brain regions underlying the distributed motor pathways within and outside the brain, including motor cortex, spinal cord, and skeletal muscles, were not examined and could account for the lack of associations of LATE-NC with some of the motor performances examined in this study. Biomarkers of LATE-NC are not available yet, and levels of LATE-NC could not be determined in life prior to decline in cognitive and motor decline. Therefore, the temporal ordering of the accumulation of LATE-NC and onset of motor decline cannot be determined. The findings are exploratory, not corrected for multiple comparisons, and will need to be confirmed in further studies.

The study has several important strengths. Approximately, 1500 older adults were annually followed for an average 7 years before death with objective repeated metrics of multiple motor performances. Moreover, we employed a novel analytic approach that examined the simultaneous changes of both cognition and different motor performances and their association with LATE-NC in the same individuals. Other study strengths were high autopsy rates, pathological assessments blinded to clinical data, and the availability of diverse indices of brain pathologies to account for in examining the associations of LATE-NC with motor and cognitive phenotypes.

**Appendix 1: Authors.**

| Name | Location | Contribution |
|---|---|---|
| **Shahram Oveisgharan, MD** | Rush University Medical Center | Design and conceptualized study; Interpretation of the data; Drafted the manuscript for intellectual content |
| **Lei Yu, PhD** | Rush University Medical Center | Analysis and interpretation of data; revising the manuscript for intellectual content |
| **Sonal Agrawal, PhD** | Rush University Medical Center | Acquisition of data; revising the manuscript for intellectual content |
| **Sukriti Nag, MD, PhD** | Rush University Medical Center | Acquisition of data; revising the manuscript for intellectual content |
| **David A. Bennett, MD** | Rush University Medical Center | Acquisition of data; revising the manuscript for intellectual content |
| **Aron S. Buchman, MD** | Rush University Medical Center | Acquisition of data; Interpretation of the data; revising the manuscript for intellectual content |
| **Julie A. Schneider, MD** | Rush University Medical Center | Acquisition of data; Interpretation of the data; revising the manuscript for intellectual content |



WNL-2023-000509_sup ---- http://links.lww.com/WNL/D63

## REFERENCES


1. Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503–1527.

2. Nelson PT, Brayne C, Flanagan ME, et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. Epub 2022 Jun 13.

3. Josephs KA, Murray ME, Tosakulwong N, et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol. 2019;137:227–238.

4. Goutman SA, Hardiman O, Al-Chalabi A, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:465–479.

5. Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol. 2022;21:258–272.

6. Polkey MI, Lyall RA, Yang K, Johnson E, Leigh PN, Moxham J. Respiratory Muscle Strength as a Predictive Biomarker for Survival in Amyotrophic Lateral Sclerosis. Am J Respir Crit Care Med. 2017;195:86–95.

7. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586–590.

8. Seelaar H, Schelhaas HJ, Azmani A, et al. TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain. 2007;130:1375–1385.

9. Besser LM, Teylan MA, Nelson PT. Limbic Predominant Age-Related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations. J Neuropathol Exp Neurol. 2020;79:305–313.

10. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64:S161–S189.

11. Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA. Sex differences in Alzheimer's disease and common neuropathologies of aging. Acta Neuropathol. 2018;136:887–900.

12. Oveisgharan S, Capuano AW, Nag S, et al. Association of hemoglobin A1C with TDP-43 pathology in community-based elders. Neurology. 2021;96:e2694–e2703.

13. Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease. Acta Neuropathol Commun. 2018;6:33.

14. Agrawal S, Yu L, Kapasi A, et al. Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change and microvascular pathologies in community-dwelling older persons. Brain Pathol. 2021;31:e12939.

15. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology. 2003;60:246–252.

16. Hyman BT, Trojanowski JQ. Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease: J Neuropathol Exp Neurol . 1997;56:1095–1097.

17. Nag S, Yu L, Capuano AW, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol. 2015;77:942–952.

18. Oveisgharan S, Yu L, Wang T, Schneider JA, Bennett DA, Buchman AS. Neurodegenerative and cerebrovascular brain pathologies are differentially associated with declining grip strength and gait in older adults. J Gerontol A Biol Sci Med Sci. Epub 2022 Jun 8.:glac128.

19. Oveisgharan S, Yu L, Capuano A, et al. Late-life vascular risk score in association with postmortem cerebrovascular disease brain pathologies. Stroke. 2021;52:2060–2067.

20. Oveisgharan S, Yu L, Barnes LL, et al. Association of statins with cerebral atherosclerosis and incident parkinsonism in older adults. Neurology. Epub 2022 Mar 23.:10.1212/WNL.0000000000200182.

21. von Oertzen T, Hertzog C, Lindenberger U, Ghisletta P. The effect of multiple indicators on the power to detect inter-individual differences in change. Br J Math Stat Psychol. 2010;63:627–646.

22. Buchman AS, Wang T, Yu L, Leurgans SE, Schneider JA, Bennett DA. Brain pathologies are associated with both the rate and variability of declining motor function in older adults. Acta Neuropathol. 2020;140:587–589.

23. Boyle PA, Wilson RS, Buchman AS, et al. Lower extremity motor function and disability in mild cognitive impairment. Exp Aging Res. 2007;33:355–371.

24. Buchman AS, Yu L, Wilson RS, et al. Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies. Neurology. 2019;92:e1821–e1830.

25. Oveisgharan S, Buchman AS, Yu L, et al. APOE epsilon2epsilon4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults. Neurology. 2018;90:e2127–e2134.

26. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269.

27. James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain. 2016;139:2983–2993.

28. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimers Dement. 2015;11:70–98.

29. Yu L, Boyle PA, Leurgans SE, Wilson RS, Bennett DA, Buchman AS. Incident Mobility Disability, Mild Cognitive Impairment, and Mortality in Community-Dwelling Older Adults. Neuroepidemiology. 2019;53:55–62.

30. Amador-Ortiz C, Lin W-L, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61:435–445.

31. Agrawal S, Yu L, Nag S, et al. The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer's dementia in older persons. Acta Neuropathol Commun. 2021;9:156.

32. Teylan MA, Mock C, Gauthreaux K, et al. Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP. J Neuropathol Exp Neurol. 2021;80:1024–1032.

33. Buchman AS, Yu L, Oveisgharan S, Farfel JM, Schneider JA, Bennett DA. Person-Specific Contributions of Brain Pathologies to Progressive Parkinsonism in Older Adults. J Gerontol A Biol Sci Med Sci. 2021;76:615–621.

34. Buchman AS, Leurgans SE, Boyle PA, Schneider JA, Arnold SE, Bennett DA. Combinations of motor measures more strongly predict adverse health outcomes in old age: the rush memory and aging project, a community-based cohort study. BMC medicine. 2011;9:42.

35. Buchman AS, Dawe RJ, Leurgans SE, et al. Different Combinations of Mobility Metrics Derived From a Wearable Sensor Are Associated With Distinct Health Outcomes in Older Adults. J Gerontol A Biol Sci Med Sci. 2020;75:1176–1183.

36. Yu L, De Mazancourt M, Hess A, et al. Functional connectivity and information flow of the respiratory neural network in chronic obstructive pulmonary disease. Hum Brain Mapp. 2016;37:2736–2754.

37. Del Negro CA, Funk GD, Feldman JL. Breathing matters. Nat Rev Neurosci. 2018;19:351–367.

38. Dhingra RR, Dick TE, Furuya WI, Galán RF, Dutschmann M. Volumetric mapping of the functional neuroanatomy of the respiratory network in the perfused brainstem preparation of rats. J Physiol. 2020;598:2061–2079.

39. Schwarzacher SW, Rüb U, Deller T. Neuroanatomical characteristics of the human pre-Bötzinger complex and its involvement in neurodegenerative brainstem diseases. Brain. 2011;134:24–35.

40. Josephs KA, Murray ME, Whitwell JL, et al. Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol. 2016;131:571–585.

41. Buchman AS, Wilson RS, Boyle PA, Bienias JL, Bennett DA. Grip Strength and the Risk of Incident Alzheimer's Disease. Neuroepidemiology. 2007;29:66–73.

42. Ward NS, Frackowiak RSJ. Age-related changes in the neural correlates of motor performance. Brain. 2003;126:873–888.

43. Pinto S, Gromicho M, Oliveira Santos MO, Swash M, De Carvalho M. Respiratory onset in amyotrophic lateral sclerosis: clinical features and spreading pattern. Amyotroph Lateral Scler Frontotemporal Degener. Epub 2022 May 5.:1–5.

44. Hannaford A, Higashihara M, Pavey N, et al. Split-hand index: A diagnostic and prognostic marker in amyotrophic lateral sclerosis across varying regions of onset. Clin Neurophysiol. 2021;132:2130–2135.

45. Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368–380.

46. Murakami A, Koga S, Sekiya H, et al. Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology. Brain Pathol. Epub 2022 Jun 17.:e13100.

47. Buciuc M, Whitwell JL, Baker MC, Rademakers R, Dickson DW, Josephs KA. Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition. Neuropathol Appl Neurobiol. 2021;47:1050–1059.

48. Arseni D, Hasegawa M, Murzin AG, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601:139–143.

49. Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6:28.

**Table 1.** Characteristics of study participants.

| Characteristics | LATE-NC stages 0-1 (n=979)[a] | LATE-NC stages 2-3 (n=504)[a] | Total (N=1483)[a] |
|---|---|---|---|
| | Mean (SD), Median (Q1-Q3), or n (%) | | |
| ***Demographic*** | | | |
| Age at death (years), mean (SD) | 89.0 (6.6) | 92.3 (5.4) | 90.1 (6.4)*** |
| Age at the last visit (years), mean (SD) | 88.2 (6.6) | 91.3 (5.6) | 89.2 (6.5)*** |
| Female, n (%) | 658 (67.2) | 373 (74.0) | 1031 (69.5)** |
| ***Clinical characteristics at the last visit*** | | | |
| Dementia, n (%) | 358 (36.6) | 324 (64.3) | 682 (46.0)*** |
| Hand strength, mean (SD) | 0.70 (0.32) | 0.60 (0.31) | 0.67 (0.32)*** |
| Grip strength, mean (SD) | 34.2 (18.5) | 27.5 (16.3) | 31.9 (18.0)*** |
| Pinch strength, mean (SD) | 8.5 (5.0) | 7.2 (4.6) | 8.1 (4.9)*** |
| Hand dexterity, mean (SD) | 0.78 (0.26) | 0.69 (0.30) | 0.75 (0.28)*** |
| Rate of finger tapping, mean (SD) | 48.8 (12.5) | 45.5 (15.6) | 47.7 (13.7)*** |
| Purdue Pegboard test score, mean (SD) | 7.0 (3.2) | 6.3 (3.2) | 6.8 (3.2)*** |
| Gait function, mean (SD) | 0.64 (0.33) | 0.61 (0.30) | 0.63 (0.32)* |
| Time to turn 360°, mean (SD) | 0.12 (0.08) | 0.11 (0.07) | 0.12 (0.8)* |
| Steps to complete 360° turn, mean (SD) | 0.09 (0.03) | 0.08 (0.03) | 0.08 (0.03) |
| Time to walk 8 feet, mean (SD) | 0.15 (0.09) | 0.14 (0.08) | 0.15 (0.09)* |
| Steps to complete walking 8 feet, mean (SD) | 0.12 (0.04) | 0.12 (0.04) | 0.12 (0.04) |
| Respiratory muscles strength, mean (SD) | 81.8 (34.2) | 72.3 (31.1) | 78.3 (33.4)*** |
| Inspiratory muscles strength, mean (SD) | 33.2 (18.6) | 27.8 (15.5) | 31.2 (17.7)*** |
| Expiratory muscles strength, mean (SD) | 56.5 (24.4) | 50.2 (21.5) | 54.2 (23.6)*** |
| Square root of Parkinsonism score, mean (SD) | 3.7 (1.4) | 3.9 (1.5) | 3.8 (1.5) |
| Presence of bradykinesia, n (%) | 415 (42.4) | 234 (46.4) | 649 (43.8) |
| Presence of rigidity, n (%) | 230 (23.5) | 139 (27.6) | 369 (24.9) |
| Presence of tremor, n (%) | 286 (29.2) | 130 (25.8) | 416 (28.1) |
| Presence of parkinsonian gait, n (%) | 696 (71.1) | 373 (74.0) | 1069 (72.1) |
| Global cognition, mean (SD) | -0.77 (1.11) | -1.47 (1.20) | -1.01 (1.19)*** |
| ***Postmortem indices of brain pathologies*** | | | |
| Alzheimer's disease, n (%) | 588 (60.1) | 387 (76.8) | 975 (65.8)*** |
| Hippocampal sclerosis, n (%) | 20 (2.1) | 118 (23.5) | 138 (9.3)*** |
| Parkinson's disease, n (%) | 77 (8.2) | 46 (9.6) | 123 (8.6) |
| One or more macroinfarcts, n (%) | 353 (36.1) | 188 (37.3) | 541 (36.5) |
| One or more microinfarcts, n (%) | 304 (31.1) | 177 (35.1) | 481 (32.4) |
| Moderate to severe atherosclerosis, n (%) | 313 (32.0) | 176 (34.9) | 489 (33.0) |
| Moderate to severe arteriolosclerosis, n (%) | 290 (29.8) | 169 (33.6) | 459 (31.1) |
| Moderate to severe cerebral amyloid angiopathy, n (%) | 330 (34.1) | 222 (44.1) | 552 (37.5)*** |

To compare lower with higher stages of LATE-NC in the characteristics, $\chi^2$ (for categorical characteristics) and t-test (for continuous characteristics) were used. ***: <0.001; **: <0.01; *: <0.05. [a]Respiratory muscle strength data were available in 483 (LATE-NC stages 0-1), 281 (LATE-NC stages 2-3), and 764 (total) participants.

**Table 2.** Association of LATE-NC with longitudinal changes of motor function in older adults.

| Outcome | Model 1-No other pathology | | Model 2-Including all pathologies | |
|---|---|---|---|---|
| | Estimate (SE), P-value | | Estimate (SE), P-value | |
| | Rate of decline | Level of outcome prior to death | Rate of decline | Level of outcome prior to death |
| **Hand strength** | -0.007 (0.002), <0.001 | -0.057 (0.016), <0.001 | -0.005 (0.002), 0.005 | -0.035 (0.017), 0.039 |
| **Hand dexterity** | -0.005 (0.001), 0.002 | -0.042 (0.013), 0.002 | -0.003 (0.002), 0.095 | -0.019 (0.014), 0.178 |
| **Gait function** | -0.004 (0.002), 0.030 | -0.021 (0.018), 0.254 | -0.004 (0.002), 0.037 | -0.016 (0.019), 0.413 |
| **Parkinsonism** | 0.022 (0.007), 0.003 | 0.085 (0.076), 0.274 | 0.014 (0.008), 0.073 | 0.019 (0.081), 0.815 |
| **Respiratory muscles strength** | -0.896 (0.296), 0.003 | -8.243 (2.539), 0.001 | -0.857 (0.322), 0.008 | -7.081 (2.713), 0.009 |

In 2 series of 5 separate mixed effects models, we examined associations of LATE-NC with longitudinal changes or motor functions. In each model, one of the motor functions (left column) was the outcome. The series of model 1 included terms for age at death, sex, time (rate of motor function change), LATE-NC, and interactions of age, sex, and LATE-NC with time. The series of model 2 included all the model 1 terms, 8 terms for other pathologies (Alzheimer's disease, hippocampal sclerosis, Parkinson's disease, macroinfarcts, microinfarcts, atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy), and 8 terms for interaction of each pathology with time.

**Table 3. Association of LATE-NC with decline rates of respiratory muscle strength (respiratory muscle strength), hand strength, and global cognition in multivariate random coefficients models with 3 outcomes.**

| Pathologies | Estimate (SE), P-value | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | Model1-LATE-NC | | | Model2-Other Paths | | | Model3-All Paths | | |
| | respiratory muscle strength | Hand Strength | Global Cognition | respiratory muscle strength | Hand Strength | Global Cognition | respiratory muscle strength | Hand Strength | Global Cognition |
| **LATE-NC** | **-0.025 (0.009), 0.004** | -0.003 (0.002), 0.177 | **-0.041 (0.008), <0.001** | NA | NA | NA | **-0.021 (0.009), 0.023** | -0.002 (0.003), 0.390 | **-0.026 (0.008), 0.003** |
| **Alzheimer's disease** | NA | NA | NA | **-0.022 (0.009), 0.019** | -0.002 (0.003), 0.449 | **-0.059 (0.008), <0.001** | **-0.020 (0.009), 0.031** | -0.002 (0.003), 0.482 | **-0.057 (0.008), <0.001** |
| **Hippocampal sclerosis** | NA | NA | NA | -0.018 (0.014), 0.220 | -0.006 (0.004), 0.124 | **-0.051 (0.013), <0.001** | -0.005 (0.015), 0.721 | -0.005 (0.004), 0.251 | **-0.036 (0.014), 0.008** |
| **Parkinson's disease** | NA | NA | NA | -0.017 (0.018), 0.344 | -0.006 (0.005), 0.228 | **-0.070 (0.015), <0.001** | -0.018 (0.018), 0.333 | -0.006 (0.005), 0.232 | **-0.071 (0.015), <0.001** |
| **Macroscopic infarcts** | NA | NA | NA | -0.015 (0.009), 0.101 | -0.001 (0.003), 0.592 | -0.005 (0.008), 0.575 | -0.016 (0.009), 0.079 | -0.002 (0.003), 0.554 | -0.006 (0.008), 0.488 |
| **Microscopic infarcts** | NA | NA | NA | -0.005 (0.009), 0.547 | -0.002 (0.002), 0.365 | -0.003 (0.008), 0.711 | -0.005 (0.009), 0.555 | -0.002 (0.002), 0.353 | -0.003 (0.008), 0.673 |
| **Atherosclerosis** | NA | NA | NA | -0.016 (0.010), 0.123 | 0.003 (0.003), 0.373 | -0.017 (0.009), 0.052 | -0.015 (0.010), 0.148 | 0.003 (0.003), 0.373 | -0.017 (0.009), 0.052 |
| **Arteriolosclerosis** | NA | NA | NA | -0.000 (0.009), 0.984 | -0.003 (0.003), 0.223 | **-0.023 (0.009), 0.007** | 0.001 (0.009), 0.879 | -0.003 (0.003), 0.251 | **-0.021 (0.008), 0.011** |
| **Cerebral** | NA | NA | NA | -0.007 | 0.001 | **-0.018** | -0.007 | 0.001 | **-0.018** |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| **amyloid angiopathy** | | | | (0.009), 0.407 | (0.003), 0.698 | **(0.008), 0.023** | (0.009), 0.433 | (0.003), 0.675 | **(0.008), 0.028** |

Each model shows a single multivariate normal coefficients model with 3 outcomes: respiratory muscle strength, hand strength, and global cognition. The terms for pathologies included in each model were different: Model1 included only LATE-NC, Model2 included indices of 8 other pathologies, and Model3 included all the pathologies. Each model also included terms for time (rate of change in the outcome), cross-sectional terms for age at death and sex, and interaction of time with age at death, sex, and corresponding pathologies listed in the left column. Except the last row, other cells show the Estimate, Standard Error and p-Value for the interaction of the corresponding pathology with time to show whether the pathology was associated with rate of decline in either of the outcomes. Bolded cells were significant.

**Figure 1. The association of LATE-NC with hand strength decline.**

Panels A and B illustrate raw trajectories of hand strength assessments in 50 randomly-selected participants without (A) and with (B) LATE-NC stages 2-3. The overlaid black line shows the average trajectory of hand strength decline in these participants derived from mixed effects models. Panel C illustrates the trajectories of hand strength decline in 3 average 90 year-old women derived from a mixed effects model: A woman without significant brain pathologies (the gray solid line), a woman with only LATE-NC stages 2-3 (the black dotted line), and a woman with all the brain pathologies (the black solid line).



**Figure 2. The association of LATE-NC with respiratory muscle strength decline.**

Panels A and B illustrate raw trajectories of respiratory muscle strength assessments in 50 randomly-selected participants without (A) and with (B) LATE-NC stages 2-3. The overlaid black line shows the average trajectory of respiratory muscle strength decline in these participants derived from mixed effects models. Panel C illustrates the trajectories of respiratory muscle strength decline in 3 average 90 year-old women derived from a mixed effects model: A woman without significant brain pathologies (the gray solid line), a woman with only LATE-NC stages 2-3 (the black dotted line), and a woman with all the brain pathologies (the black solid line).



# Relation of Motor Impairments to Neuropathologic Changes of Limbic-Predominant Age-Related TDP-43 Encephalopathy in Older Adults

Shahram Oveisgharan, Lei Yu, Sonal Agrawal, et al.

*Neurology* published online August 21, 2023
DOI 10.1212/WNL.0000000000207726